Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTE Aerovate Therapeutics	$7.36 -1.9%	$8.65	$56.35 ▼ $105.00	$213.33M	0.95	12,438 shs	84,262 shs
IGMS IGM Biosciences	$1.27	$1.27	$0.92 ▼ $22.50	$76.57M	0.6	480,746 shs	N/A
JAN JanOne		$2.57	$0.22 ▼ $5.26	$20.03M	2.16	229,417 shs	139,500 shs
WHWK Whitehawk Therapeutics	$1.65	$0.00	$1.39 ▼ $3.81	$77.76M	0.55	153,636 shs	301,878 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTE Aerovate Therapeutics	+1.90%	+1.35%	-20.80%	-2.79%	-88.35%
IGMS IGM Biosciences	0.00%	-2.31%	-0.78%	+7.63%	-86.76%
JAN JanOne	0.00%	0.00%	0.00%	0.00%	0.00%
WHWK Whitehawk Therapeutics	+2.48%	-3.51%	-8.33%	+164,999,900.00%	+164,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IGMS IGM Biosciences	4.5063 of 5 stars	3.0	3.0	0.0	4.6	3.0	3.3	1.3
JAN JanOne	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
WHWK Whitehawk Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTE Aerovate Therapeutics	0.00	N/A	N/A	N/A
IGMS IGM Biosciences	1.90	Reduce	$5.50	333.07% Upside
JAN JanOne	0.00	N/A	N/A	N/A
WHWK Whitehawk Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest JAN, WHWK, IGMS, and AVTE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/11/2025	WHWK Whitehawk Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell

(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	$3.96 per share	N/A
IGMS IGM Biosciences	$145.05M	0.53	N/A	N/A	$1.67 per share	0.76
JAN JanOne	$39.61M	0.00	N/A	N/A	($0.67) per share	0.00
WHWK Whitehawk Therapeutics	$25.98M	2.99	N/A	N/A	$3.65 per share	0.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTE Aerovate Therapeutics	-$75.52M	-$1.70	N/A	N/A	N/A	N/A	-90.19%	-77.47%	N/A
IGMS IGM Biosciences	-$195.79M	-$0.90	N/A	N/A	N/A	-36.81%	-93.35%	-24.15%	N/A
JAN JanOne	-$7.81M	N/A	0.00	N/A	N/A	N/A	-359.71%	-70.26%	N/A
WHWK Whitehawk Therapeutics	-$63.69M	-$0.06	N/A	∞	N/A	99.42%	-75.99%	-68.57%	N/A

Latest JAN, WHWK, IGMS, and AVTE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/7/2025	Q2 2025	WHWK Whitehawk Therapeutics	$0.49	-$0.76	-$1.25	-$0.76	$100.00 million	N/A
7/31/2025	Q2 2025	IGMS IGM Biosciences	-$0.30	$1.58	+$1.88	$1.58	$3.20 million	$143.62 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A
IGMS IGM Biosciences	N/A	N/A	N/A	N/A	N/A
JAN JanOne	N/A	N/A	N/A	N/A	N/A
WHWK Whitehawk Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTE Aerovate Therapeutics	N/A	8.78	8.78
IGMS IGM Biosciences	N/A	17.66	17.66
JAN JanOne	N/A	0.15	0.15
WHWK Whitehawk Therapeutics	N/A	20.41	20.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTE Aerovate Therapeutics	N/A
IGMS IGM Biosciences	42.79%
JAN JanOne	6.27%
WHWK Whitehawk Therapeutics	52.08%

Insider Ownership

Company	Insider Ownership
AVTE Aerovate Therapeutics	24.90%
IGMS IGM Biosciences	57.00%
JAN JanOne	3.00%
WHWK Whitehawk Therapeutics	49.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTE Aerovate Therapeutics	20	28.99 million	21.69 million	Optionable
IGMS IGM Biosciences	190	60.29 million	25.93 million	Optionable
JAN JanOne	170	8.98 million	8.71 million	Not Optionable
WHWK Whitehawk Therapeutics	40	47.13 million	23.61 million	N/A

JAN, WHWK, IGMS, and AVTE Headlines

Recent News About These Companies

Whitehawk Therapeutics (NASDAQ:WHWK) Rating Lowered to Strong Sell at Wall Street Zen

August 11, 2025 | americanbankingnews.com

Whitehawk Therapeutics (NASDAQ:WHWK) Announces Quarterly Earnings Results, Misses Expectations By $1.25 EPS

August 10, 2025 | marketbeat.com

Whitehawk Therapeutics (NASDAQ:WHWK) Downgraded to "Strong Sell" Rating by Wall Street Zen

August 10, 2025 | marketbeat.com

Whitehawk Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

August 7, 2025 | prnewswire.com

Whitehawk Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

July 22, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JAN, WHWK, IGMS, and AVTE Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

$7.36 -0.14 (-1.87%)

As of 08/19/2025

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

IGM Biosciences NASDAQ:IGMS

$1.27 0.00 (0.00%)

As of 08/14/2025

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

JanOne NASDAQ:JAN

JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. It operates through Biotechnology and Recycling segments. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. It also provides turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs. The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019. JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada.

Whitehawk Therapeutics NASDAQ:WHWK

$1.65 0.00 (0.00%)

As of 04:00 PM Eastern

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time